CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roden, R. B.
Right arrow Articles by Metcalfe, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roden, R. B.
Right arrow Articles by Metcalfe, J. C.

Cell Growth & Differentiation, Vol 4, Issue 12 957-964, Copyright © 1993 by American Association of Cancer Research


ARTICLES

A common requirement for p21c-ras function in the mitogenic signaling pathways of Swiss 3T3 fibroblasts

RB Roden, Y Shachar-Hill, SC Cosulich, TR Hesketh and JC Metcalfe
Department of Biochemistry, University of Cambridge, United Kingdom.

The role of p21c-ras in the activation of DNA synthesis in quiescent Swiss 3T3 fibroblasts was examined by scrape loading or microinjecting the neutralizing monoclonal antibody Y13-259 into the cells. Y13-259 delayed but did not block both the serum-stimulated entry of the cells into S phase and the accumulation of cdc2 mRNA and protein at the G1-S boundary. Introduction of Y13-259 also stimulated expression of sufficient p21c-ras to neutralize the loaded antibody; this finding suggests that the delay of S phase is attributable to the time taken to synthesize an excess of p21c-ras over the antibody and implies autoregulation of c-ras expression. Y13-259 had no effect upon phosphoinositide-mediated responses ([Ca2+]i increase and activation of protein kinase C) to platelet-derived growth factor or bombesin, demonstrating that p21c-ras is not required for mitogen activation of protein kinase C. Y13-259 inhibited 5-bromo-2'-deoxyuridine incorporation in response to all of the combinations of mitogens used to stimulate quiescent cells (fetal calf serum, platelet-derived growth factor, and the combination of insulin with 12-O-tetradecanoylphorbol-13-acetate, bombesin, epidermal growth factor, or prostaglandin E1), indicating that p21c-ras functions on pathways common to all of the effective combinations of mitogens examined.


This article has been cited by other articles:


Home page
J. Immunol.Home page
D. G. Woodside and B. W. McIntyre
Inhibition of CD28/CD3-Mediated Costimulation of Naive and Memory Human T Lymphocytes by Intracellular Incorporation of Polyclonal Antibodies Specific for the Activator Protein-1 Transcriptional Complex
J. Immunol., July 15, 1998; 161(2): 649 - 658.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
K. C. Malcolm, C. M. Elliott, and J. H. Exton
Evidence for Rho-mediated Agonist Stimulation of Phospholipase D in Rat1 Fibroblasts: EFFECTS OF CLOSTRIDIUM BOTULINUM
J. Biol. Chem., May 31, 1996; 271(22): 13135 - 13139.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1993 by the American Association of Cancer Research.